CN102781962B - 双互补位A-β结合多肽 - Google Patents
双互补位A-β结合多肽 Download PDFInfo
- Publication number
- CN102781962B CN102781962B CN201180012034.7A CN201180012034A CN102781962B CN 102781962 B CN102781962 B CN 102781962B CN 201180012034 A CN201180012034 A CN 201180012034A CN 102781962 B CN102781962 B CN 102781962B
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- seq
- vhh
- cdr
- immunoglobulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Abstract
Description
SEQ ID NO: | 氨基酸序列 |
11 | TDTMG |
12 | AVTWNSGRTNYADSVKG |
13 | HRLVVGGTSVGDWRY |
14 | TDTMG |
15 | AVTWNSGRINYADSVKG |
16 | HRFVVGGNRVEDWRY |
17 | NYNMG |
18 | AVSRSGVSTYYADSVKG |
19 | AYRGTAINVRRSYSS |
组1 | 组2 | 组3 | 组4 | |
CDR(1)1 | 11 | 14 | 17 | 17 |
CDR(1)2 | 12 | 15 | 18 | 18 |
CDR(1)3 | 13 | 16 | 19 | 19 |
CDR(2)1 | 17 | 17 | 11 | 14 |
CDR(2)2 | 18 | 18 | 12 | 15 |
CDR(2)3 | 19 | 19 | 13 | 16 |
ABII42G10 | 1-16 | 87.0 | 49.5 | >1000 |
ABII60A10 | 12-28 | 4.9 | 0.8 | 11.1 |
ABII60G11 | 12-28 | 187 | 6.0 | 34.4 |
ABII60D2 | 1-16 | >1μM | ND | ND |
ABII60H5 | 1-16 | >1μM | ND | ND |
ABII61F6 | 12-28 | 469 | 14.5 | 967* |
2D2 | 12-28 | 15.8 | 4.7 | 404* |
2G6 | 1-16 | 98.6 | 7.2 | >1000 |
Fab266 | 16-24* | 1.8 | 1.8 | 0.52 |
Fab3D6 | 1-5* | 1.8 | 0.3 | 3.4 |
Claims (23)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10155339 | 2010-03-03 | ||
EP10155339.4 | 2010-03-03 | ||
PCT/EP2011/053090 WO2011107507A1 (en) | 2010-03-03 | 2011-03-02 | Biparatopic abeta binding polypeptides |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102781962A CN102781962A (zh) | 2012-11-14 |
CN102781962B true CN102781962B (zh) | 2014-12-10 |
Family
ID=42227600
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201180012034.7A Expired - Fee Related CN102781962B (zh) | 2010-03-03 | 2011-03-02 | 双互补位A-β结合多肽 |
Country Status (24)
Country | Link |
---|---|
US (3) | US8337845B2 (zh) |
EP (1) | EP2542579A1 (zh) |
JP (2) | JP5826194B2 (zh) |
KR (1) | KR20130010114A (zh) |
CN (1) | CN102781962B (zh) |
AP (1) | AP2012006359A0 (zh) |
AR (1) | AR080446A1 (zh) |
AU (1) | AU2011222980B2 (zh) |
BR (1) | BR112012022102A2 (zh) |
CA (1) | CA2788275A1 (zh) |
CL (1) | CL2012002095A1 (zh) |
CO (1) | CO6592094A2 (zh) |
EA (1) | EA201201227A1 (zh) |
EC (1) | ECSP12012184A (zh) |
HK (1) | HK1175184A1 (zh) |
MA (1) | MA34025B1 (zh) |
MX (1) | MX2012009460A (zh) |
NZ (1) | NZ601117A (zh) |
PE (1) | PE20130527A1 (zh) |
SG (1) | SG183369A1 (zh) |
TN (1) | TN2012000434A1 (zh) |
TW (1) | TW201144437A (zh) |
UY (1) | UY33253A (zh) |
WO (1) | WO2011107507A1 (zh) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR080446A1 (es) | 2010-03-03 | 2012-04-11 | Boehringer Ingelheim Int | Polipeptidos de union a a-beta (beta amiloide) |
EP2621953B1 (en) | 2010-09-30 | 2017-04-05 | Ablynx N.V. | Biological materials related to c-met |
US11644471B2 (en) * | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
AU2012271974B2 (en) | 2011-06-23 | 2017-01-12 | Ablynx Nv | Serum albumin binding proteins |
SG10201805064SA (en) | 2011-06-23 | 2018-07-30 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
US9346884B2 (en) | 2011-09-30 | 2016-05-24 | Ablynx N.V. | Biological materials related to c-Met |
KR102104686B1 (ko) | 2012-01-10 | 2020-04-24 | 바이오젠 엠에이 인코포레이티드 | 뇌혈관 장벽을 통한 치료학적 분자의 수송 개선법 |
US10407508B2 (en) | 2013-07-08 | 2019-09-10 | Nanjing Legend Biotech., Ltd. | Compositions and methods for increasing protein half-life in a serum |
NZ726448A (en) | 2014-05-16 | 2023-02-24 | Ablynx Nv | Improved immunoglobulin variable domains |
PT3248986T (pt) | 2014-05-16 | 2022-04-05 | Ablynx Nv | Domínios variáveis de imunoglobulina |
US11001640B2 (en) * | 2014-11-03 | 2021-05-11 | Merck Patent Gmbh | Methods for generating bispecific shark variable antibody domains and use thereof |
WO2016077595A1 (en) * | 2014-11-12 | 2016-05-19 | The General Hospital Corporation | Methods for treating neurodegenerative diseases |
CN104558172A (zh) * | 2015-01-04 | 2015-04-29 | 东南大学 | 一种针对β淀粉样蛋白的单域重链纳米抗体及其应用 |
JP6640232B2 (ja) * | 2015-02-06 | 2020-02-05 | ユニバーシティ オブ メリーランド,ボルチモア | クロストリジウム・ディフィシル感染症の治療のための、クロストリジウム・ディフィシルのトキシンa及びトキシンbに対する四重特異性の八量体型結合剤及び抗体 |
CN112649538B (zh) * | 2015-04-28 | 2024-03-29 | 深圳翰宇药业股份有限公司 | 多肽混合物高效液相色谱分析方法 |
UA122079C2 (uk) | 2015-12-04 | 2020-09-10 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Поліпептид, що специфічно зв'язується з lrp5 і lrp6 |
EA201992808A1 (ru) | 2017-05-31 | 2020-05-14 | Бёрингер Ингельхайм Интернациональ Гмбх | ПОЛИПЕПТИДЫ, ПРЕПЯТСТВУЮЩИЕ ПЕРЕДАЧЕ Wnt СИГНАЛОВ В ОПУХОЛЕВЫХ КЛЕТКАХ |
WO2019016237A1 (en) * | 2017-07-19 | 2019-01-24 | Vib Vzw | AGENTS FOR CONNECTING TO SERUM ALBUMIN |
EP3758755A1 (en) * | 2018-02-26 | 2021-01-06 | Ablynx N.V. | Improved nucleotide sequences encoding peptide linkers |
EP3836966A4 (en) * | 2018-08-17 | 2022-06-08 | Ab Studio Inc. | CATALYTIC ANTIBODIES AND THEIR METHODS OF USE |
MA54070A (fr) * | 2018-10-29 | 2021-09-08 | Biogen Ma Inc | Variants fc5 humanisés et stabilisés pour l'amélioration du transport à travers la barrière hémato-encéphalique |
CN111334480B (zh) * | 2020-05-18 | 2020-09-01 | 苏州仁端生物医药科技有限公司 | 一种分泌抗Aβ1-42单克隆抗体的杂交瘤细胞株及其应用 |
MX2023000949A (es) | 2020-07-23 | 2023-02-22 | Othair Prothena Ltd | Anticuerpos anti-beta-amiloide (abeta). |
CN113686235B (zh) * | 2021-08-16 | 2022-09-16 | 中国科学院力学研究所 | 一种基于纳米孔过孔电流估计蛋白质构象形貌特征的方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101076543A (zh) * | 2004-10-13 | 2007-11-21 | 阿布林克斯公司 | 用于治疗和诊断变性神经疾病如阿尔茨海默症的单结构域骆驼抗淀粉样蛋白β的抗体以及包含它的多肽 |
CN101213214A (zh) * | 2005-05-20 | 2008-07-02 | 埃博灵克斯股份有限公司 | 针对冯威勒布兰特因子的单一结构域vhh抗体 |
CN101370525A (zh) * | 2005-08-19 | 2009-02-18 | 艾博特公司 | 双重可变结构域免疫球蛋白及其用途 |
CN102112494A (zh) * | 2008-06-03 | 2011-06-29 | 雅培制药有限公司 | 双重可变结构域免疫球蛋白及其用途 |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2162823T5 (es) | 1992-08-21 | 2010-08-09 | Vrije Universiteit Brussel | Inmunoglobulinas desprovistas de cadenas ligeras. |
EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
US6329516B1 (en) | 1997-04-28 | 2001-12-11 | Fmc Corporation | Lepidopteran GABA-gated chloride channels |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
EP1276849A4 (en) | 2000-04-12 | 2004-06-09 | Human Genome Sciences Inc | ALBUMIN FUSION PROTEINS |
WO2002057445A1 (en) | 2000-05-26 | 2002-07-25 | National Research Council Of Canada | Single-domain brain-targeting antibody fragments derived from llama antibodies |
PE20020574A1 (es) | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
DE60237282D1 (de) | 2001-06-28 | 2010-09-23 | Domantis Ltd | Doppelspezifischer ligand und dessen verwendung |
JP4123856B2 (ja) | 2001-07-31 | 2008-07-23 | 日油株式会社 | 生体関連物質の修飾剤およびポリオキシアルキレン誘導体の製造方法 |
EP1463752A4 (en) | 2001-12-21 | 2005-07-13 | Human Genome Sciences Inc | ALBUMIN FUSION PROTEINS |
AR038568A1 (es) * | 2002-02-20 | 2005-01-19 | Hoffmann La Roche | Anticuerpos anti-a beta y su uso |
MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
FR2846667B1 (fr) | 2002-11-06 | 2004-12-31 | Pasteur Institut | Fragments variables d'anticorps de camelides a chaine unique diriges contre le peptide beta-amyloide 1-42 et leurs applications pour le diagnostic et le traitement des maladies neuroagregatives |
AU2003286003B2 (en) | 2002-11-08 | 2011-05-26 | Ablynx N.V. | Stabilized single domain antibodies |
WO2005044858A1 (en) | 2003-11-07 | 2005-05-19 | Ablynx N.V. | Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor |
JP2006524036A (ja) | 2002-11-08 | 2006-10-26 | アブリンクス エン.ヴェー. | 腫瘍壊死因子αを標的とする単一ドメイン抗体およびその使用 |
US7432330B2 (en) | 2002-12-31 | 2008-10-07 | Nektar Therapeutics Al, Corporation | Hydrolytically stable maleimide-terminated polymers |
EP2390270A1 (en) * | 2003-01-10 | 2011-11-30 | Ablynx N.V. | Therapeutic polypeptides, homologues thereof, fragments thereof and for use in modulating platelet-mediated aggregation |
TWI374893B (en) | 2003-05-30 | 2012-10-21 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
PT1639011E (pt) | 2003-06-30 | 2009-01-20 | Domantis Ltd | Anticorpos (dab) de domínio único peguilados |
AR047062A1 (es) | 2003-12-17 | 2006-01-04 | Wyeth Corp | Conjugados portadores de peptidos inmunogenicos a beta y metodos para producirlos |
WO2006040153A2 (en) | 2004-10-13 | 2006-04-20 | Ablynx N.V. | Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease |
TW200636066A (en) | 2004-12-15 | 2006-10-16 | Elan Pharm Inc | Humanized antibodies that recognize beta amyloid peptide |
PE20061401A1 (es) | 2004-12-15 | 2006-12-23 | Neuralab Ltd | ANTICUERPOS Aß PARA MEJORAR LA COGNICION |
TW200635607A (en) | 2004-12-15 | 2006-10-16 | Elan Pharm Inc | Humanized Aβ antibodies for use in improving cognition |
WO2006081171A1 (en) | 2005-01-24 | 2006-08-03 | Amgen Inc. | Humanized anti-amyloid antibody |
GT200600031A (es) | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
MY148086A (en) | 2005-04-29 | 2013-02-28 | Rinat Neuroscience Corp | Antibodies directed against amyloid-beta peptide and methods using same |
AU2006249144B2 (en) | 2005-05-18 | 2011-11-17 | Ablynx Nv | Improved NanobodiesTM against Tumor Necrosis Factor-alpha |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
EP1934611A2 (en) | 2005-09-23 | 2008-06-25 | Academisch Ziekenhuis Leiden | Vhh for the diagnosis, prevention and treatment of diseases associated with protein aggregates |
RU2015111675A (ru) | 2005-12-12 | 2015-08-10 | Ац Иммуне Са | Специфические в отношении амилоида бета (а бета) 1-42 моноклональные антитела, обладающие терапевтическими свойствами |
RS52004B (en) | 2005-12-12 | 2012-04-30 | F. Hoffmann-La Roche Ag | ANTIBODIES AGAINST AMYLOID BETA WITH GLYCOSILATION IN THE VARIABLE REGION |
EP2177536B1 (en) | 2006-03-30 | 2014-06-04 | Glaxo Group Limited | Antibodies against amyloid-beta peptide |
KR101605207B1 (ko) | 2006-07-14 | 2016-03-22 | 에이씨 이뮨 에스.에이. | 아밀로이드 베타에 대해 인간화된 항체 |
US8629244B2 (en) | 2006-08-18 | 2014-01-14 | Ablynx N.V. | Interleukin-6 receptor binding polypeptides |
JP2010511397A (ja) | 2006-12-05 | 2010-04-15 | アブリンクス エン.ヴェー. | 血清タンパク質と結合可能なペプチド |
MX2009006199A (es) | 2006-12-11 | 2009-06-22 | Hoffmann La Roche | Formulacion parenteral de anticuerpos abeta. |
AU2007331672A1 (en) * | 2006-12-15 | 2008-06-19 | Ablynx N.V. | Amino acid sequences that modulate the interaction between cells of the immune system |
PT2842967T (pt) | 2007-01-18 | 2017-01-13 | Lilly Co Eli | Fab beta amilóide peguilado |
EP1978035A1 (en) | 2007-04-05 | 2008-10-08 | Hans-Knöll-Institut Leibniz-Institut für Naturstoff-Forschung | Anti-amyloid antibodies and their use in diagnosis and therapy of amyloid diseases |
CN104231082B (zh) | 2007-05-24 | 2018-12-21 | 埃博灵克斯股份有限公司 | 用于治疗骨疾病和病症的针对rank-l的氨基酸序列以及包括其的多肽 |
PE20090329A1 (es) | 2007-05-30 | 2009-03-27 | Abbott Lab | Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos |
CN101820911B (zh) | 2007-06-12 | 2015-05-06 | Ac免疫有限公司 | β淀粉样蛋白的人源化抗体 |
BRPI0812484A2 (pt) | 2007-06-12 | 2018-06-05 | Ac Immune Sa | anticorpo monoclonal, regiões variáveis de cadeia leve e de cadeia pesada, cdr isolada, polinucleotídeo, composição terapêutica, métodos para tratar doenças e distúrbios, para produzir um anticorpo, para tratar ou aliviar os efeitos de doenças e distúrbios, para reduzir a carga de placas no cérebro de um indivíduo, para reduzir a quantidade de placas no cérebro de um indivíduo, para diminuir a quantidade total de abeta solúvel no cérebro de um indivíduo, para reter ou aumentar a capacidade de memória cognitiva em um indivíduo, de diagnose de ou para diagnosticar uma predisposição para uma doença associada com amilóide ou condição em um paciente, para determinar a extensão de carga de placa amiloidogênica em um tecido de um indivíduo, para monitorar doença residual mínima em um indivíduo e para prever responsividade de um indivíduo, linhagem de células, kit de teste, epítopo abeta |
EP2008666A1 (en) * | 2007-06-29 | 2008-12-31 | Institut Pasteur | Use of VHH antibodies for the preparation of peptide vectors for delivering a substance of interest and their applications |
EP2009445A1 (en) | 2007-06-29 | 2008-12-31 | Institut Pasteur | Use of a camelid single-domain antibody for detecting an oligomeric form of an amyloid beta peptide and its applications |
JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
EP2205633A1 (en) | 2007-10-29 | 2010-07-14 | Innogenetics N.V. | New antibodies specific of the -amyloid peptides and their uses as diagnostic agents or drugs |
EP2650311A3 (en) * | 2007-11-27 | 2014-06-04 | Ablynx N.V. | Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same |
GB2470328A (en) | 2008-03-05 | 2010-11-17 | Ablynx Nv | Novel antigen binding dimer complexes, methods of making and uses thereof |
WO2009127691A1 (en) | 2008-04-17 | 2009-10-22 | Ablynx N.V. | Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same |
AR080446A1 (es) | 2010-03-03 | 2012-04-11 | Boehringer Ingelheim Int | Polipeptidos de union a a-beta (beta amiloide) |
-
2011
- 2011-03-02 AR ARP110100659A patent/AR080446A1/es unknown
- 2011-03-02 WO PCT/EP2011/053090 patent/WO2011107507A1/en active Application Filing
- 2011-03-02 CN CN201180012034.7A patent/CN102781962B/zh not_active Expired - Fee Related
- 2011-03-02 CA CA2788275A patent/CA2788275A1/en not_active Abandoned
- 2011-03-02 UY UY0001033253A patent/UY33253A/es not_active Application Discontinuation
- 2011-03-02 AP AP2012006359A patent/AP2012006359A0/xx unknown
- 2011-03-02 MX MX2012009460A patent/MX2012009460A/es not_active Application Discontinuation
- 2011-03-02 EP EP11708226A patent/EP2542579A1/en not_active Ceased
- 2011-03-02 SG SG2012061024A patent/SG183369A1/en unknown
- 2011-03-02 US US13/038,471 patent/US8337845B2/en active Active
- 2011-03-02 EA EA201201227A patent/EA201201227A1/ru unknown
- 2011-03-02 AU AU2011222980A patent/AU2011222980B2/en not_active Ceased
- 2011-03-02 TW TW100106954A patent/TW201144437A/zh unknown
- 2011-03-02 NZ NZ601117A patent/NZ601117A/en not_active IP Right Cessation
- 2011-03-02 MA MA35176A patent/MA34025B1/fr unknown
- 2011-03-02 JP JP2012555410A patent/JP5826194B2/ja not_active Expired - Fee Related
- 2011-03-02 KR KR1020127023071A patent/KR20130010114A/ko not_active Application Discontinuation
- 2011-03-02 BR BR112012022102A patent/BR112012022102A2/pt not_active IP Right Cessation
- 2011-03-02 PE PE2012001380A patent/PE20130527A1/es not_active Application Discontinuation
-
2012
- 2012-07-27 CL CL2012002095A patent/CL2012002095A1/es unknown
- 2012-08-31 TN TNP2012000434A patent/TN2012000434A1/en unknown
- 2012-09-04 CO CO12151313A patent/CO6592094A2/es unknown
- 2012-09-14 US US13/617,248 patent/US8614308B2/en active Active
- 2012-09-27 EC ECSP12012184 patent/ECSP12012184A/es unknown
-
2013
- 2013-02-26 HK HK13102375.6A patent/HK1175184A1/zh not_active IP Right Cessation
- 2013-08-29 US US14/013,364 patent/US9211330B2/en active Active
-
2015
- 2015-07-06 JP JP2015134933A patent/JP2015180691A/ja active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101076543A (zh) * | 2004-10-13 | 2007-11-21 | 阿布林克斯公司 | 用于治疗和诊断变性神经疾病如阿尔茨海默症的单结构域骆驼抗淀粉样蛋白β的抗体以及包含它的多肽 |
CN101213214A (zh) * | 2005-05-20 | 2008-07-02 | 埃博灵克斯股份有限公司 | 针对冯威勒布兰特因子的单一结构域vhh抗体 |
CN101370525A (zh) * | 2005-08-19 | 2009-02-18 | 艾博特公司 | 双重可变结构域免疫球蛋白及其用途 |
CN102112494A (zh) * | 2008-06-03 | 2011-06-29 | 雅培制药有限公司 | 双重可变结构域免疫球蛋白及其用途 |
Also Published As
Publication number | Publication date |
---|---|
SG183369A1 (en) | 2012-09-27 |
TW201144437A (en) | 2011-12-16 |
CL2012002095A1 (es) | 2012-10-19 |
MA34025B1 (fr) | 2013-02-01 |
CA2788275A1 (en) | 2011-09-09 |
US9211330B2 (en) | 2015-12-15 |
AU2011222980A1 (en) | 2012-08-02 |
JP2013520974A (ja) | 2013-06-10 |
AP2012006359A0 (en) | 2012-08-31 |
EP2542579A1 (en) | 2013-01-09 |
BR112012022102A2 (pt) | 2017-01-10 |
US20140030275A1 (en) | 2014-01-30 |
US20130017209A1 (en) | 2013-01-17 |
UY33253A (es) | 2011-09-30 |
US8614308B2 (en) | 2013-12-24 |
AU2011222980B2 (en) | 2016-08-11 |
ECSP12012184A (es) | 2012-10-30 |
AR080446A1 (es) | 2012-04-11 |
KR20130010114A (ko) | 2013-01-25 |
MX2012009460A (es) | 2012-09-12 |
JP5826194B2 (ja) | 2015-12-02 |
JP2015180691A (ja) | 2015-10-15 |
HK1175184A1 (zh) | 2013-06-28 |
EA201201227A1 (ru) | 2013-04-30 |
CN102781962A (zh) | 2012-11-14 |
PE20130527A1 (es) | 2013-05-09 |
WO2011107507A1 (en) | 2011-09-09 |
CO6592094A2 (es) | 2013-01-02 |
US20120058118A1 (en) | 2012-03-08 |
US8337845B2 (en) | 2012-12-25 |
NZ601117A (en) | 2014-06-27 |
TN2012000434A1 (en) | 2014-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102781962B (zh) | 双互补位A-β结合多肽 | |
TWI516500B (zh) | 抗β類澱粉蛋白單株抗體 | |
CN101998863B (zh) | 抗淀粉状蛋白β抗体在眼病中的用途 | |
TWI729992B (zh) | 用於治療共核蛋白病的藥劑、用途及方法 | |
CN109618556B (zh) | 特异性针对过度磷酸化τ蛋白的抗体及其使用方法 | |
TWI634126B (zh) | 抗-N3pGlu 類澱粉β肽抗體及其用途 | |
CN101883791B (zh) | 人源化抗体 | |
CN104650225B (zh) | 用于结合鞘氨醇-1-磷酸的组合物和方法 | |
KR102602502B1 (ko) | 신경퇴행성 장애의 치료를 위한 세마포린-4d 결합 분자의 용도 | |
CN101883790B (zh) | 抗淀粉样蛋白β抗体在眼病中的用途 | |
AU2018370279B2 (en) | Antibodies to a-synuclein and uses thereof | |
CN104761641A (zh) | β淀粉样蛋白的人源化抗体 | |
JP2020195399A (ja) | Kv1.3結合免疫グロブリン | |
Medecigo et al. | Novel amyloid-beta specific scFv and VH antibody fragments from human and mouse phage display antibody libraries | |
TW201946654A (zh) | 抗PHF-Tau抗體及其用途 | |
CN103524617B (zh) | 针对淀粉状蛋白β的人源化抗体 | |
EP3990488A1 (en) | Semaphorin 3a antibodies and uses thereof | |
TW202216760A (zh) | 抗類澱粉β (ABETA)抗體 | |
KR20210153039A (ko) | 커넥신 43 항체 및 이의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1175184 Country of ref document: HK |
|
ASS | Succession or assignment of patent right |
Owner name: ABLYNX N. V. Free format text: FORMER OWNER: BOEHRINGER INGELHEIM INT Effective date: 20141028 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20141028 Address after: Belgium zwijnaarde Applicant after: ABLYNX N.V. Address before: In Germany Applicant before: BOEHRINGER INGELHEIM INTERNATIONAL GmbH |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1175184 Country of ref document: HK |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20141210 |
|
CF01 | Termination of patent right due to non-payment of annual fee |